SCHEMBL6888962

SCHEMBL6888962

COC(=O)c1cccc2c1C(S(=O)(=O)O)c1ccccc1-2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.45
KMT2A Q03164 2/20 0.45
MAPT P10636 2/20 0.45
MEN1 O00255 1/20 0.45
HTT P42858 1/20 0.45
MAPK10 P53779 1/20 0.45
PTK2B Q14289 1/20 0.45
NCOA1 Q15788 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
NCOA3 Q9Y6Q9 1/20 0.45
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA5A P35218 1/20 0.43
CA9 Q16790 1/20 0.43
ALDH1A1 P00352 2/20 0.43
HSD17B10 Q99714 2/20 0.43
KDM4E B2RXH2 2/20 0.43
PTPRC P08575 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL45391 0.76 HTR7 (0.36) KMT2AMEN1NPSR1CA1CA2
SCHEMBL3165966 0.73 TTR (0.35) TSHRSMN1; SMN2CA1CA2POLB
SCHEMBL2319486 0.73 NCOR2 (0.42) TSHRKMT2AMAPTMEN1HTT
SCHEMBL29945031 0.73 NCOR2 (0.42) TSHRKMT2AMAPTMEN1HTT
SCHEMBL1683233 0.72 ALDH1A1 (0.49) KMT2AMAPTMEN1SMN1; SMN2ALDH1A1
Dimethyl Phthalate SCHEMBL27641225 0.71 CA1 (0.63) TSHRKMT2AMAPTCA1CA2
SCHEMBL8697389 0.70 AKR1B1 (0.41) TSHRMAPT
SCHEMBL1934600 0.70 ALDH1A1 (0.40) TSHRKMT2AMAPTMEN1HTT
SCHEMBL114462 0.70 CA1 (0.35) KMT2AMAPTHTTSMN1; SMN2NPSR1
SCHEMBL5818114 0.70 CA1 (0.33) CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6696605-B2 CATALYTICALLY REACTING POLYMER SUPPORTED ISOCYANIDE WITH ALDEHYDE; OPTIONALLY OXIDIZING; CLEAVING NITROGEN RESIN BOND THE PROCTER & GAMBLE COMPANY 2004-02-24 US claimed
US-20030176739-A1 Process for preparing alpha-hydroxyamides and alpha-ketoamides on a solid phase support THE PROCTER & GAMBLE COMPANY 2003-09-18 US claimed
US-6696605-B2 CATALYTICALLY REACTING POLYMER SUPPORTED ISOCYANIDE WITH ALDEHYDE; OPTIONALLY OXIDIZING; CLEAVING NITROGEN RESIN BOND THE PROCTER & GAMBLE COMPANY 2004-02-24 US disclosed
US-20030176739-A1 Process for preparing alpha-hydroxyamides and alpha-ketoamides on a solid phase support THE PROCTER & GAMBLE COMPANY 2003-09-18 US disclosed
US-5684127-A SELECTIVELY PROTECTING AMINO GROUPS AND PHENOLIC HYDROXY GROUPS OF A PENTAPEPTIDE, OXIDIZING THE HYDROXYMETHYL MOIETY OF PROTECTED PENTAPEPTIDE TO CARBOXY, DEPROTECTING AMINO GROUP AND SUBMITTING COMPOUND TO DEGRADATION GRUPPO LEPETIT SPA (IT) 1997-11-04 US disclosed
US-5644025-A AGLYCON DALBAHEPTIDE ANTIBIOTICS FOR CYCLIC TETRAPEPTIDES FOR BACTERICIDES GRUPPO LEPETIT SPA (IT) 1997-07-01 US disclosed
EP-0363211-B1 1Alpha or 24R,25-Dihydroxy vitamin D3 derivatives, process for their production and assay method using the same ASAHI CHEMICAL IND (JP) 1994-07-06 EP disclosed
US-5214170-A Radioimmunoassay TOYO JOZO KABUSHIKI KAISHA (JP) 1993-05-25 US disclosed
US-5202266-A 25-hydroxy vitamin D3 derivatives, process for their production, and assay method using the same ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1993-04-13 US disclosed
EP-0312360-B1 25-HYDROXY VITAMIN D3 DERIVATIVES TOYO JOZO KABUSHIKI KAISHA (JP) 1992-06-17 EP disclosed
US-5117018-A 1α (or 24R), 25-dihydroxy vitamin D3 derivatives TOYO JOZO KABUSHIKI KAISHA (JP) 1992-05-26 US disclosed
US-5075465-A 25-HYDROXY VITAMIN D3 DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND ASSAY METHOD USING THE SAME TOYO JOZO KABUSHIKI KAISHA (JP) 1991-12-24 US disclosed
EP-0363211-A1 1Alpha or 24R,25-Dihydroxy vitamin D3 derivatives, process for their production and assay method using the same ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1990-04-11 EP disclosed
EP-0312360-A2 25-Hydroxy vitamin D3 derivatives TOYO JOZO KABUSHIKI KAISHA (JP) 1989-04-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176739-A1 Process for preparing alpha-hydroxyamides and alpha-ketoamides on a solid phase support KDM8, HACL2, HAAO TSHR 4202/4885KMT2A 19/4885MAPT 3156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.